echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Gilead 2019 financial report: hepatitis C decline, hepatitis B drug vemlidy gradually become a new force! Expansion fulcrum of car-t oncogenic business

    Gilead 2019 financial report: hepatitis C decline, hepatitis B drug vemlidy gradually become a new force! Expansion fulcrum of car-t oncogenic business

    • Last Update: 2020-02-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On February 4, Geely announced its 2019 results, with a total annual revenue of $22.449 billion, an increase of 1.5% compared with 2018 Among them, the sales revenue of AIDS products reached US $16.438 billion, an increase of 12% compared with 2018, and the proportion in the company's total revenue increased to 73.32%, which is Geely's core business segment Hepatitis C drugs, which once accounted for half of Gilead's business at a brilliant time, continued to decline, with sales revenue of $2.936 billion in 2019, down another 20% year on year With the approval of hepatitis B drug vemlidy in China, it has opened up the world's largest market and achieved 52% growth Geely expects to generate $1 billion in revenue in 2022 as it penetrates the U.S market and drives the Chinese market In 2019, the sales volume of Geely's main drugs (US $100 million) continued to upgrade its anti viral drug ammunition base, while facing the competition of GSK Looking back at 2019's performance, almost all of them rely on biktarvy, a four in one AIDS drug, to maintain the overall stable performance of the company and make up for the overall decline of other products In addition to the AIDS business and hepatitis B drug vemlidy, Geely's biggest surprise is cell therapy yescarta, which is late but first, and continues to maintain the market leading position This performance is not only because the number of patients in the US market continues to increase, but also because the EU market has opened up a situation Yescarta's revenue in Europe is $83 million in 2019 and only $1 million in 2018 Another market increment of Gilead comes from China Since 2017, Gilead has successively obtained the approval of China's NMPA for 8 drugs, and 4 new drugs have entered the national health insurance catalogue, including Vemlidy for hepatitis B, Epclusa for hepatitis C, Harvoni for hepatitis C and Genvoya for AIDS In view of the fact that the business of hepatitis C has become a thing of the past, Gilead will focus on anti-virus, inflammatory diseases, tumor and fibrotic diseases in the future On March 1, 2019, Daniel O'Day, the former CEO of Roche pharmaceutical, formally took over the post of CEO of Geely, and began to layout according to the established strategy The first one is the personnel change Daniel has made a great adjustment to Geely's core senior team CSO, CPO, COO and HRD are all old people changing their looks (see: Gilead's senior shock) Until October 2019, when he announced the appointment of merdad parsey as the global chief medical officer, Geely's new senior team was completed This series of personnel changes is also considered by Gilead as one of its key actions in 2019 In addition, Gilead 's major actions in 2019 also include the independent operation of Kite and the invitation of Christi Shaw, the former head of Lilly' s biopharmaceutical business, to serve as the CEO of Kite In addition, Gilead expanded its cooperation with Galapagos and established a 10 year R & D partnership (see: $5 billion 50 million! Gilead and Galapagos) Glpg1690, a phase III idiopathic pulmonary fibrosis drug, was obtained In terms of pipeline research and development, Geely's three most important products in the next two years are filgotinib, a Jak1 inhibitor acquired from Galapagos, yescarta (Axi CEL) and kte-x19 acquired from kite Among them, filgtotinib will release the data of stage III ulcerative enteritis in the first half of this year, which will be approved by FDA in the second half of this year; Axi cel's stage II NHL data will be published in the first half of this year; breakthrough therapy kte-x19 is expected to obtain FDA approval in the second half of this year These three products are not only Geely's new performance growth point, but also the cornerstone of Geely's transformation Especially in the early stage of other tumor candidate drugs, car-t products are the fulcrum of Gilead's business expansion in the field of tumor In the field of inflammatory diseases, Gilead has built a solid drug pipeline through cooperation with Galapagos In the field of cancer, Gilead has experienced the defeat brought by zydelig, a small molecule drug, and now it mainly relies on cell therapy to open up the market situation But in addition to cell therapy, Gilead's tumor pipeline also has some small molecule drugs and antibody drug reserves based on tumor immunotherapy, such as oral PD-L1 inhibitor gs-4224 Although it is still in the early stage, it also indicates that the tumor will be a business that Geely will continue to build As of December 31, 2019, Gilead still has $25.84 billion of cash assets (including cash equivalents and marketable debt securities) on its books, which also makes Gilead have the conditions to continue to seek external project cooperation and transaction M & A opportunities around its strategic positioning in 2020.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.